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TRABECTOME (TRABECULECTOMY⎯INTERNAL APPROACH): ADDITIONAL EXPERIENCE AND 
EXTENDED FOLLOW-UP  
BY Don Minckler MD MS,* Sameh Mosaed MD, Laurie Dustin MS, Brian Francis MD MS, AND the Trabectome Study Group† 
ABSTRACT 
Purpose: To report a retrospective case series of 1127 Trabectome surgical procedures, including 738 Trabectome-only and 366 
Trabectome-phacoemulsification surgeries. 
Methods: Electroablation of meshwork via a temporal corneal incision. Outcomes included changes in intraocular pressure (IOP) and 
medication use, complications, and Kaplan-Meier success estimates.  
Results: For all cases, mean preoperative IOP of 23.8 ± 7.7 mm Hg decreased by 39% to 16.5 ± 4.0 mm Hg at 24 months (n = 50). 
Intraoperative reflux bleeding occurred in 77.6%. Medications decreased from 2.8 to 1.2 by 24 months. Sixty-five patients (5.8%) had 
IOP elevation > 10 mm Hg above baseline on day 1. Failure led to trabeculectomy in 5.9% (n = 67) and shunt installation in 1.6% (n = 
18). Kaplan-Meier failure was defined across groups with at least 2 weeks follow-up as IOP > 21 mm Hg with or without medications 
and not reduced by 20% below baseline on 2 consecutive visits or repeat surgery.  
For Trabectome-only cases, mean preoperative IOP of 25.7 ± 7.7 mm Hg was reduced by 40% to 16.6 ± 4.0 mm Hg at 24 months (n = 
46). No prolonged hypotony, choroidal effusion, choroidal hemorrhage, or infections occurred. Failure led to trabeculectomy in 8.1% 
(n = 60) and shunt installation in 1.9% (n = 14). Medications decreased from 2.93 to 1.2 by 24 months.  
For Trabectome-phacoemulsification cases, baseline IOP of 20.0 ± 6.2 mm Hg decreased at 12 months to 15.9 ± 3.3 mm Hg (18%) (n 
= 45) and medications decreased from 2.63 ± 1.12 to 1.50 ± 1.36. Sixteen (4.4%) of 365 had prior failed trabeculectomy, and 139 of 
365 (38%) had prior laser trabeculoplasty. 
Conclusion: Trabectome offers a minimally invasive method of improving IOP control in open-angle glaucomas.  
Trans Am Ophthalmol Soc 2008;106:149-160 
INTRODUCTION 
The Trabectome, cleared by the US Food and Drug Administration in April 2004, was first used in the United States in January 2006 
for surgical treatment of open-angle glaucoma. Now in its third year of widening commercialization and clinical utilization in all age-
groups, it has been employed in 46 glaucoma centers in the United States, Canada, Mexico, and Japan. Three peer-reviewed 
publications have described and illustrated the instrument, intraocular pressure (IOP) outcomes in the initial 37 cases performed in 
Mexico, and a subsequent case series expanded to 89 patients with 30 months follow-up for 10 eyes from among the original 37 
cases.1-3 The unique aspect of this procedure includes the electrosurgical ablation of trabecular meshwork and debris aspiration to 
improve aqueous access to collector channels, most numerous nasally.4,5 Also, the device’s footplate protects adjacent tissues during 
ablation. This report includes demographics on the overall group and separate descriptive statistics and survival analyses for 
Trabectome-only and combined Trabectome-phacoemulsification cases. 
METHODS 
Data for this report have been collected with local Institutional Review Board approval, in accordance with the Declaration of Helsinki 
and the Health Insurance Portability and Accountability Act. Procedure modifications that have been recommended since the 
previously published method descriptions include topical application of apraclonidine 0.5% or brimonidine 0.1% per surgeon 
preference to reduce intraoperative reflux bleeding. Among early cases, anesthesia was usually induced via retrobulbar needle or sub-
Tenon irrigation. Now intracameral preservative-free lidocaine 1% to 2% is often used. Hydroxymethylcellulose (OcuCoat, Bausch & 
Lomb, Rochester, NY) has remained the recommended viscoelastic, if needed, to deepen and stabilize the anterior chamber. A Simcoe 
cannula is now included with the surgical pack for use as needed to remove residual blood after Trabectome-only surgery. With 
experience, most surgeons experienced in Trabectome use now report treating 60o to 120o of angle. Technique variations since the 
original reports have included use of higher power levels during tissue ablation, now averaging 700 to 800 mW, as well as deferring 
the use of viscoelastic in the anterior chamber of pseudophakic eyes, as it is usually not necessary. 
Topical medications used before surgery are resumed or titrated downward postoperatively, according to surgeon preference, 
depending on the desired IOP goal range.  
PATIENTS 
Typical candidates for Trabectome surgery are phakic or pseudophakic eyes of adults or children with uncontrolled open-angle 
glaucoma and a clear gonioscopic view. Demographic data for all cases, including combined procedures, are summarized in Table 1. 
The age range of patients was 3 days to 96 years, with a mean age of 69 ± 15 years. Many eyes at relatively high risk for filtering 
From the Gavin Herbert Eye Institute and University of California, Irvine (Dr Minckler, Dr Mosaed), and the Departments of Ophthalmology (Dr Francis) and 
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surgery failure were included after prior failed trabeculectomy or other previous surgeries.  
Eyes with extensive peripheral anterior synechiae covering the meshwork were excluded, but a few eyes with limited peripheral 
anterior synechiae were included and three combined Trabectome-phacoemulsification procedures included goniosynechialysis (Table 
1). 
 
TABLE 1. CHARACTERISTICS OF PATIENTS WITH 
UNCONTROLLED OPEN-ANGLE GLAUCOMA 
TREATED WITH TRABECTOME 
VARIABLE VALUE 
Total number 1127 
Age  
Mean 69 yr 
SD 15 yr 
Minimum 3 days 
Maximum  96 yr 




Race (self-defined)  








(Not stated) 18 
Glaucoma type  
POAG 818 
Exfoliation 109 
Juvenile rheumatoid arthritis 5 
Steroid-induced 20 
Pigment dispersion 37 
Uveitis-related 29 
Other (not indicated) 109 
Other ocular diagnosis  
Myopic degeneration 5 
CRVO 1 
Preop Snellen acuity  
20/20 – 20/40 538 
20/50 – 20/70 203 
20/80 – 20/100 68 
20/200 – 20/400 91 
<20/400 54 
Not reported 173 
Visual field status (damage)  
Minimal (1 quadrant) 57 
Moderate (2 quadrants) 270 
Advanced (>2 quadrants) 372 
Not reported 428 
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TABLE 1 (CONTINTUED) CHARACTERISTICS OF 
PATIENTS WITH UNCONTROLLED OPEN-ANGLE 
GLAUCOMA TREATED WITH TRABECTOME 
VARIABLE VALUE 





Not reported 238 
Cup-disc ratio  
<0.7 221 
0.7 – 0.8 337 
>0.8 425 
Not reported 144 
Prior surgery  
SLT 273 
ALT 170 
Aqueous shunt 20 
Trabeculectomy 104 
Prior Trabectome 5 
Vitrectomy 4 
Laser iridectomy 5 
Endocyclophotocoagulation 3 
YAG capsulotomy 2 
Retinal surgery 15 
Combined surgeries  
Trabectome-phaco 366 
Trabectome- goniosynechialysis 3 
Aqueous shunt at same operation 7 
Trabectome and PK 1 
Trabectome and ECP 1 
Trabectome and bleb revision 2 
ALT, argon laser trabeculoplasty; CRVO, central retinal vein 
occlusion; ECP, endolaser cyclophotocoagulation; PK, penetrating 
keratoplasty; POAG, primary open-angle glaucoma; SLT, selective 
laser trabeculoplasty. 
STATISTICAL METHODS 
Summaries of changes in IOP and medication use (Tables 1 through 3; Figures 1 through 8) include Kaplan-Meier survival graphs for 
all cases (Figure 3), Trabectome-only cases (Figure 4), and Trabectome-phacoemulsification cases (Figure 5). Survival graphs were 
calculated using SAS 9.1 (SAS Institute, Cary, North Carolina). Failure (definition 1) was IOP greater than 21 mm Hg and not 
reduced by 20% below baseline on 2 consecutive visits after 2 weeks follow-up or subsequent surgery, similar to the definitions 
utilized in the recent Tube Versus Trabeculectomy (TVT) study.6,7 We also included a survival analysis (definition 2) with failure 
defined as IOP greater than 21 mm Hg or not reduced by 20% below baseline on 2 consecutive visits after 2 weeks follow-up or 
subsequent surgery (Figure 8). Mean change in IOP from baseline and decrease in medication use are shown in Table 2 for 
Trabectome-only and in Table 3 for combined Trabectome-phacoemulsification cases by follow-up month. 
RESULTS 
The decrease in IOP among Trabectome-only cases with or without medications was 40% at 24 months (n = 46) (Table 2), 41% at 36 
months (n = 35), and 32% at 60 months (n = 2) to 16.4 ± 4.5 mm Hg, down from a mean preoperative IOP of 25.7 ± 7.7 mm Hg 
(Table 2, Figure 1). The mean decrease in adjunctive medication use for Trabectome-only cases was 39%, from a preoperative mean 
of 2.9 ± 1.30 to a postoperative mean of 1.8 ± 1.4 antiglaucoma medications (Table 2, Figure 2). Failure, defined as additional 
glaucoma surgery (Trabectome, trabeculectomy, aqueous shunt, laser trabeculoplasty, cyclophotocoagulation), has been reported in 
100 of 738 Trabectome-only cases (14%) (Table 2). Twelve of 100 surgical failures occurred by 2 weeks, 76 of 100 by 6 months, and 
95 of 100 by 18 months, demonstrating that clinical failure defined by a subsequent glaucoma surgery is most likely during the first 
postoperative year (Table 2). Two patients (3 eyes) in the study have died since the original report in 2005.  
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TABLE 2. CHANGES IN INTRAOCULAR PRESSURE (IOP) AND MEDICATION USE 
 AFTER TRABECTOME-ONLY SURGERY  
IOP (MM HG) SECOND SURGERY MEDICATION USE TIME OF 
EXAMINATION MEAN SD 
% 
REDUCTION N CUMULATIVE 
NO. 






25.7 7.7  738   2.93 1.29 
1 day 16.6 8.8 -31% 699 1 0 2.04 1.71 
3 days 16.7 6.9 -31% 649 1 0 2.17 1.70 
1 wk 16.9 6.8  -315 656 2 0 2.55 1.57 
2 wk 17.7 6.9 -27% 610 12 2 2.56 1.54 
1 mo 17.3 6.0 -28% 571 23 3 2.41 1.46 
2 mo 16.5 5.3 -31% 494 42 6 2.24 1.42 
3 mo 16.5 4.7 -31% 425 53 7 2.16 1.44 
4 mo 16.4 4.2 -31% 353 65 9 2.01 1.38 
5 mo 16.4 4.0 -32% 296 73 10 1.96 1.38 
6 mo 16.5 4.2 -31% 260 76 10 1.84 1.41 
7 mo 16.3 3.6 -32% 212 86 12 1.83 1.39 
8 mo 16.0 3.7 -34% 181 86 12 1.80 1.45 
9 mo 15.8 3.3 -36% 147 90 12 1.66 1.43 
10 mo 15.8 3.6 -37% 129 90 12 1.51 141 
11 mo 16.0 3.1 -37% 111 90 12 1.41 1.36 
12 mo 16.1 3.0 -37% 102 93 13 1.50 1.27 
15 mo 16.0 3.1 -38% 87 93 13 1.44 1.19 
18 mo 16.1 2.9 -40% 67 95 13 1.22 1.13 
21 mo 16.2 3.4 -42% 54 96 13 1.35 1.05 
24 mo 16.6 4.0 -40% 46 97 13 1.24 0.92 
30 mo 16.6 3.0 -40% 40 98 13 1.23 0.97 
36 mo 16.4 2.7 -41% 35 98 13 1.00 0.94 
40 mo 16.6 3.0 -40% 32 99 13 1.03 1.03 
44 mo 15.9 2.1 -41% 28 100 14 0.82 0.82 
48 mo 16.1 1.9 -40% 20 100 14 0.89 0.81 
52 mo 16.3 2.2 -37% 13 100 14 1.15 0.80 
56 mo 16.1 1.4 -36% 8 100 14 0.88 0.64 
60 mo 17.5 0.7 -32% 2 100 14 0.50 0.71 
Mean 16.4 4.5 -35%     1.8  
SD   4%      1.4 
 
Mean preoperative IOP among combined Trabectome-phacoemulsification cases (Table 3) with or without medications decreased 
21% at 6 months (n = 143), 18% at 12 months (n = 45), and an overall mean of 20%, from 20.0 ± 6.2 mm Hg to 15.5 ± 4.0 mm Hg at 
30 months (Table 3). Medication use decreased from a preoperative mean of 2.93 ± 1.29 to 2.0 ± 2.83 at 30 months. 
Complications and adverse events among all cases to date have included transient elevation of IOP, defined as IOP exceeding 10 mm 
above baseline at day 1, reported in 65 of 1127 cases (5.8%) (Table 4). Intraoperative blood reflux has occurred in most eyes (78%) 
but typically cleared over a few days and has not consistently correlated with IOP elevation. Visual acuity decrease (≥2 Snellen lines) 
due to progression of cataract after Trabectome surgery was reported in 1 among 101 cases included in the 2006 update3 that 
underwent cataract surgery 21 months post-Trabectome. Visual acuity decrease ≥2 Snellen lines has not been reported after 
subsequent Trabectome surgery. No cases of postoperative endophthalmitis or choroidal hemorrhage have been reported.  
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TABLE 3. CHANGES IN INTRAOCULAR PRESSURE (IOP) AND MEDICATION USE AFTER COMBINED 
TRABECTOME-PHACOEMULSIFICATION SURGERY 
IOP (MM HG) SECOND SURGERY MEDICATION USE TIME OF 












20.0 6.2  366   2.93 1.29 
1 day 17.8 9.0 -7% 355 0 0 1.67 1.57
3 days 16.9 7.2 -11% 335 2 1 1.76 1.58
1 wk 16.0 6.0 -16% 338 4 1 2.10 1.41
2 wk 15.7 5.2 -18% 322 7 2 2.15 1.38
1 mo 15.2 4.6 -20% 314 9 2 2.09 1.34
2 mo 15.1 3.8 -20% 280 10 3 1.81 1.35
3 mo 14.7 3.7 -23% 235 10 3 1.78 1.31
4 mo 14.7 3.5 -22% 191 12 3 1.71 1.36
5 mo 15.0 3.6 -20% 163 13 4 1.63 1.29
6 mo 14.8 3.2 -21% 143 13 4 1.64 1.27
7 mo 14.6 3.2 -21% 113 12 3 1.60 1.31
8 mo 15.0 3.1 -20% 102 12 3 1.65 1.35
9 mo 15.0 3.6 -20% 86 12 3 1.69 1.39
10 mo 14.7 3.1 -22% 70 12 3 1.54 1.39
11 mo 15.3 3.4 -17% 56 12 3 1.52 1.25
12 mo 15.9 3.3 -18% 45 12 3 1.50 1.36
15 mo 15.8 2.6 -17% 33 13 4 1.64 1.48
18 mo 15.8 3.2 -19% 20 13 4 1.40 1.10
21 mo 16.0 3.1 -25% 10 13 4 1.60 1.35
24 mo 14.9 3.1 -30% 4 13 4 1.25 1.89
30 mo 16.5 3.5 -42% 2 13 4 2.00 2.83
Mean 15.5 4.0 -20%    1.7 




Changes in intraocular pressure 
(IOP) in Trabectome-only cases 
(N = 738) 
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Kaplan-Meier plot of probability of success, according to failure definition 1, in all cases (N = 1127). 
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FIGURE 4 





Kaplan-Meier plot of probability of success, according to failure definition 1,  
in combined Trabectome and phacoemulsification (N = 366). 
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FIGURE 6 





Changes in adjunctive medication use in Trabectome-phacoemulsification cases (N = 366). 
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FIGURE 8 




TABLE 4. COMPLICATIONS AND ADVERSE EVENTS AMONG 
ALL CASES OF TRABECULOME SURGERY  
Total number of patients 1127 
Trabeculectomy 67 
Aqueous shunt  18 
Diode cyclophotocoagulation 3 
Selective laser trabeculoplasty 5 
Phacoemulsification 1 
Endocyclophotocoagulation 1 
ExPRESS shunt 1 
Repeat Trabectome (patient request) 10 
Trabectome with shunt ligature release 5 
Other secondary surgeries 7 
Total secondary surgeries reported  113 
Patient deaths during follow-up (unrelated) 3 
Sustained hypotony (IOP <5 mm Hg 1 mo postoperatively) 0 
Hypotony (IOP <5 mm Hg day 1) 17 
IOP spike (IOP >10 mm Hg above baseline day 1) 65 
Aqueous misdirection 1 
Infection 0 
Wound leaks 0 
Bleb formation 0 
Problematic pain 0 
Choroidal effusion 0 
Choroidal hemorrhage 0 
Visual acuity decrease >2 lines 0 
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TABLE 4 (CONTINUED). COMPLICATIONS AND ADVERSE 
EVENTS AMONG ALL CASES OF TRABECULOME SURGERY 
Intraoperative blood reflux reported (874/1127 [78%]) 874 
None noted 55 
Not reported 198 
IOP, intraocular pressure; SLT, selective laser trabeculoplasty. 
 
DISCUSSION 
Limitations of this retrospective case series include small numbers at longer-term follow-up intervals in both Trabectome-only and 
Trabectome-phacoemulsification subsets. Although the instrument supplier requires reporting of results back to the database for the 
first 20 cases performed by a participating surgeon, reporting on cases beyond the initial 20 and long-term reporting of previous cases 
are voluntary and no doubt incomplete. This update on 1127 surgeries likely did not include all cases performed by several surgeons, 
as the total number of handpieces sold by the company is much larger than 1127, even allowing for inventory of extra handpieces at 
some facilities. As with any retrospective noncomparative case series, patient selection and data collection lack the rigor and 
consistency usually practiced during a prospective randomized trial. Dwindling numbers of patients with follow-up beyond many 
months render long-term efficacy difficult to evaluate and may explain the apparent decrease in IOP standard deviation with longer-
term follow-up. Loss to follow-up has no doubt occurred but cannot be precisely tabulated, since recruitment and follow-up data 
collection are ongoing and data submission is voluntary beyond 1 year. Sample size and power calculations were not made, and no 
control group was included. Survival curves using the TVT study criterion, which compared trabeculectomy to the Baerveldt aqueous 
shunt, are included, as in many instances these alternative filtering procedures would be considered for patients such as those reported 
here. The survival curve for the entire group using failure definition 2 (“or” instead of “and”) provides a less optimistic outcome but 
more realistically portrays expected IOP decrease among those cases (especially low-tension glaucomas) starting with IOPs less than 
21 mm Hg.  
The optimum arc of angle necessary to treat is unknown. Preliminary analysis using goniophotography suggests minimal 
correlation between the ablation arc and IOP outcomes (Khaja HA, Hodge DO, Sit A, Poster 4191, ARVO annual meeting; April 27-
May 1, 2008, Fort Lauderdale, Florida). Possibly the more important issues are that the ablated areas remain open and are in proximity 
to collector channel openings. 
CONCLUSIONS 
Trabectome offers a safe and effective alternative to standard filtering surgery that importantly does not preclude subsequent 
procedures, as the conjunctiva is not manipulated. It may not be appropriate in cases thought to require especially low IOP. 
Considering that the data presented here are based primarily on the initial procedures done by new users, albeit including many with 
expertise in gonioscopy, the results are very unlikely to have been biased by high skill levels among surgeons or by selection of 
favorable cases, as many were at relatively high risk for failure (Table 1). This large case series has established that this procedure has 
low complication rates and is likely to improve IOP control on fewer medications.  
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APPENDIX 
Trabectome Study Group contributors and institutions: D. Apte MD, Kaiser Permanente, Santa Clara, CA; R.E. Bandel MD, R. Shetty 
MD, Mayo Clinic, Jacksonville, FL; E.M. Barnett MD, Washington University, St Louis, MO; C. Batiste MD, Spectra Surgery 
Center, Glendale, AZ; D. Budenz MD, Bascom Palmer Eye Institute, Miami, FL; T. Chen MD, D. Rhee MD, Mass Eye and Ear 
Infirmary–Harvard Medical School, Boston, MA; R.L. Chevrier MD, K. Damji MD, D. Marshall MD, Ottawa Hospital, Ottawa, 
Canada; J. Compagna MD, Alamo Heights Surgical Center, San Antonio, TX; F. Cotter MD, Vistar Eye Center, Roanoke, VA; N. 
Donas MD, Community Hospital, Dobbs Ferry, NY; R. Fellman MD, Glaucoma Associates of Texas, Dallas, TX; D. Friedman MD 
PhD, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD; Z. Ghiasi MD, Kaiser Permanente, Fontana CA; C. Girkin 
MD, Calahan Eye Foundation, Birmingham, AL; D. Godfrey MD, Glaucoma Associates of Texas, Dallas, TX; A. Jamil MD, M. 
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Johnstone MD, R. Mills MD, Northwest Glaucoma Consultants, Seattle, WA; L.S. Jones MD, Howard University, Washington, DC; 
Y.H. Kwon MD, University of Iowa, Iowa City, IA; D. Laroche MD, New York Eye and Ear, New York, NY; M. Leen MD, 
Silverdale Surgical Center, Silverdale, WA; M. Maeda MD, Chukyo Eye Clinic, Nagoya, Japan; B.B. Mahan MD, Harton Medical 
Hospital, TN; K. Mitchell MD, Palmetto Hospital, Columbia, SC; Q. Nguyen MD, Scripps Health Clinic, La Jolla, CA; G. 
Osmundson MD, Sioux Falls Surgical Center, Sioux Falls, SD; C. Patitsas MD, JC Blair Hospital, Huntingdon, PA; M. Ramirez MD, 
Codet Aris, Tijuana, Mexico; G. Reiss MD, Spectra Surgery Center, Glendale, AZ; R. Rosenquist MD, Kaiser Permanente, Fontana, 
CA; J. Schuman MD, University of Pittsburgh Medical Center, Pittsburgh, PA; P. Sidoti MD, New York Eye and Ear, New York, NY; 
C.J. Siegfried MD, Washington University, St Louis, MO; A. Sit MD, Mayo Clinic, Rochester, MN; M. Stiles MD, Stiles Eye Care 
Excellence, Kansas City, KS; R. Tamesis MD, Loma Linda Hospital, Loma Linda, CA; T. Tanji MD, Kapio Lani Hospital, Honolulu, 
HI; J. Trible MD, Wolfe Eye Clinic, Des Moines, IA; S.D. Vold MD, Boozman Hof Regional Eye Clinic, Rogers, AR; M. Watanabe 
MD, Chukyo Eye Clinic, Nagoya, Japan; R. Weinreb MD, Shiley Eye Institute, UCSD, La Jolla, CA; P.T. Zacharia MD, St Vincent 
Hospital, Worcester, MA.  
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PEER DISCUSSION 
DR. ANNE LOUISE COLEMAN: The authors are to be congratulated for reporting the results from post-marketing surveillance of a 
new surgical procedure for glaucoma, the Trabectome®.  The first 20 patients plus additional patients who had the Trabectome® at 46 
glaucoma centers since January 2006 were included in this manuscript if their data were available.  As with any post-market study, 
there are issues with measurement errors, missing data, and confounding by clinical indication.  The definition of failure in this study 
was designed to be similar to the one used by Dr. Gedde and co-authors in the Tube versus Trabeculectomy Study,1,2 i.e.  failure was 
defined as IOP greater than 21 mmHg and not reduced by 20% below baseline on 2 consecutive visits after 2 weeks follow-up or 
repeat surgery.  This definition of failure is concerning because it guarantees that those patients who are enrolled with an IOP of 21 
mmHg or less are less likely to fail because postoperatively they need a higher IOP than pre-operatively to meet both criteria:  IOP 
greater than 21 mmHg and not reduced by 20% below baseline.  If the definition of failure used an “or” instead of an “and”, patients 
would only need one of the criteria to fail so that patients with lower IOPs preoperatively would be as likely to fail as those with 
higher IOPs.  In this study the mean preoperative IOP was 20.0 mmHg with a standard deviation of 6.2 mmHg in patients who had a 
combined Trabectome® and phacoemulsification.  This means that a substantial proportion of subjects had IOPs less than 21 mmHg 
and were less likely to fail.  When failure is defined as IOP greater than 21 mmHg and not reduced by 20% below baseline on 2 
consecutive visits after 2 weeks follow-up or repeat surgery, there was a 75% success rate at 12 months in all Trabectome® patients 
versus when IOP greater than 21 mmHg and not reduced by 20% below baseline on 2 consecutive visits after 2 weeks follow-up or 
repeat surgery IOP greater than 21 mmHg or not reduced by 20% below baseline on 2 consecutive visits after 2 weeks follow-up or 
repeat surgery, there was 40% success at 12 months.   Although one of the goals of study design and analysis may be consistency with 
prior studies, there is a risk that relying solely on this earlier conception of “success” will induce misunderstandings with the potential 
for downstream clinical consequences.  Expanding the reporting of results by including both the  “and” and the “or” definitions or by 
including reports of success rates stratified by baseline IOP above or below a certain threshold would broaden the perspective of the 
clinical audience on the performance of the procedure.              
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DR. RICHARD L. LINDSTROM:  I consult for AMO who makes a glaucoma tube shunt and I have done some consulting for 
Glaukos and Transend, who are developing anterior chamber stents.  One of the things I have learned by participating in these projects 
is that cataract surgery alone lowers intraocular pressure more than we thought.  One of my associates, Tom Samuelson, who is a 
glaucoma specialist, and Brooks Poley and Richard Schultz, of Savannah, put together a series of about 600 eyes, from our two 
practices to determine the impact of cataract surgery alone on intraocular pressure. In the group with mean preoperative IOPs of 22 to 
30 mm Hg, phacoemulsification with a posterior chamber lens alone lowered the IOP about 7mm Hg.   I think one of the things we 
need to have, as well as the control group of just Trabectome ® or Trabectome® plus phacoemulsification, is perhaps 
phacoemulsification alone group.  I believe that phacoemulsification without a glaucoma implant lowers pressure as much as the 
glaucoma drainage device does.  This is going to require us, as we go forward, to set a higher standard for glaucoma operations.  It 
may turn out that one of the most effective glaucoma operations available is to simply take out the cataract and place a posterior 
chamber IOL. 
DR, ALBERT W. BIGLAN: No financial conflict, or other conflicts of interest.This is a very exciting instrument. Back in the late 
40’s and early 1950’s Otto Barkan used a knife to treat glaucoma.  It was initially used in chronic open-angle glaucoma or primary 
open-angle glaucoma but was later applied to the eyes of children.  When you report your data, I would encourage you to consider 
breaking out a group or cohort of children 2 years of age and younger, and to report those results separate from your adults.  Also, 
consider using a lower pressure criteria as a consideration for success, perhaps 18 to 20mm.  This is a very exciting instrument and I 
think it will prove to be of value to those of us who treat pediatric glaucoma.  Thank you for your presentation. 
 No financial conflict or other conflicts of interest.  
DR. EDWARD L. RAAB.   No conflict. I share Dr. Biglan’s enthusiasm about the possible use of this instrument in children.  I want 
to ask you about the 8-month old baby.  I assume that the surgical intervention was for the treatment of a developmental glaucoma.  If 
my assumption is correct and, unless my understanding is outdated, the possible mechanisms of developmental glaucoma in infants do 
not include abnormalities in Schlemm’s canal.  With the use of this instrument do you find it necessary to get into Schlemm’s canal 
and actually perform some ablation?  Should I infer that you think this is the mechanism that explains intraocular pressure elevation in 
congenital glaucoma? If you believe that it is, how would the application of the Trabectome® explain the success of goniotomy that 
does not involve ablation of Schlemm’s canal?   
DR. DON MINCKLER.   Perhaps I can work backwards.  Dr. Raab’s comments are well taken. I might point out there is an extensive 
literature from Sweden, of which I only recently became aware, that  suggests  most adult or many cases of adult glaucoma are 
congenital in origin by virtue of a developmental membrane. This finding presumably would be something similar to what Barkan 
described as a membrane vaulting over the meshwork in the eyes of children with congenital glaucoma.  I mention this because a few 
times we have observed a membrane-like structure peeling off the trabecular meshwork during this procedure.  The tissue that we 
have been able to recover, as I have shown briefly, is either trabecular meshwork or fragments of the meshwork and Descemet’s 
membrane.   It does not seem to be a distinct membrane.  My concept of pathogenesis in this case is that the abnormal covering of the 
trabecular meshwork by iris may have impaired aqueous humor outflow.  The procedure does not obliterate Schlemm’s canal, as far as 
we know, but rather removes a strip of trabecular meshwork and inner wall of Schlemm’s canal.  Incidentally, I had performed 
trabeculectomies after failed trabeculotomies on this child’s father when he was about five, and remarkably the father is still seeing.  
The reason we determined this child had congenital glaucoma was supported by the fact that under careful observation his globe 
enlarged.  His corneas were clear, but the corneal diameter expanded, and he developed increased disc cupping with documented 
intraocular pressures in the mid 20s.  Trabeculotomy and goniotomy, in my view, are actually variations of the same procedure, in the 
sense that you are cutting through the trabecular meshwork into Schlemm’s canal.  After reviewing Barkan’s original drawings, it is 
quite clear to me that that his concept included penetrating into Schlemm’s canal.  How could one otherwise explain the back-bleeding 
or bleeding into the anterior chamber after goniotomy in children that is rather a common intraoperative problem? With traditional ab 
externo trabeculotomy, we are obviously rupturing through the inner wall of Schlemm’s canal.  Among the other theoretical 
advantages of Trabectome® in children and adults is the removal of inflammatory debris by aspiration during the procedure and not 
leaving charred tissue in the angle.   
Dr. Biglan, perhaps these comments have answered some of the questions you had posed. I agree that we should breakout the data 
on children as soon as we have sufficient numbers. Currently we only have about 20 cases that, by some stretch of the imagination, 
could fit into this category, and we have not analyzed them separately.  At present I see relatively few babies with congenital 
glaucoma.  
Dr. Lindstrom brings up an excellent point regarding cataract extraction that alone lowers intraocular pressure.  The literature with 
which I am familiar on this subject suggests an IOP reduction of about 2 mmHg, rather than the 7 mm you quoted.  Everyone’s own 
expectations depend on whose results you accept.  In our experience with combined Trabectome® and cataract surgery, we observed 
about 5 mm Hg lowering. We believe that there is a significant difference, at least based on our own data.  We plan a randomized 
prospective trial to compare phacoemulsification alone with combined Trabectome® and phacoemulsification.  I think such a study 
will be relatively easy to complete in a multicenter manner, and we are in the process of organizing it now. 
I want to thank Anne for her comments, and indeed we have gone back and forth about how to define “success” and “failure” in 
this study.  As all of you know, adjustments in the definitions of success can make a huge difference in statistical outcomes.  The 
solution Anne suggests, providing survival curves based on both “and” and “or” criteria, makes perfect sense and would provide the 
reader with a more complete picture of the range of outcomes.  Thank you all, I have very much appreciated the discussion. 
 
